Abstract
Background: Apranax Plus® is a new bilayer tablet dosage form, which combines two active pharmaceutical ingredients: naproxen sodium and codeine phosphate.
Objective: The purpose of this work was to develop an Ultra-High-Performance Liquid Chromatography (UHPLC) method for the separation and determination of codeine phosphate hemihydrate impurities in a bilayer tablet dosage form.
Methods: The separation and determination of codeine phosphate hemihydrate and its impurities, methylcodeine, morphine, codeine dimer, 10-hydroxycodeine, 14-hydroxycodeine, thebaine and codeinone were achieved by using reversed-phase liquid chromatography with TUV (Tunable UV Detector) and PDA (Photodiode Array Detector) detection by UHPLC. The new proposed method utilized by the Waters Acquity UHPLC® TUV and PDA systems using a UHPLC column Waters Acquity, BEH, C18, 2.1x100 mm, 1.7 μm particle size with a mixture of component A and acetonitrile in a gradient mode at a flow rate of 0.3mL/min, at 25°C with a load of 5μL. The detection for all eluted compounds was carried out at 245nm.
Results: The codeine phosphate hemihydrate and peaks of its impurities were adequately obtained, thus proving the stability-indicating power of the method. The developed method was validated as per the ICH guidelines with respect to parameters such as precision, accuracy, linearity, Limit of Detection (LOD), Limit of Quantification (LOQ) and robustness.
Conclusion: It was verified as being adequate for all the mentioned impurities of codeine phosphate hemihydrate. The described method was found to be useful for routine purity testing and was also found suitable for the analysis of the stability samples of the drug product.
Keywords: Codeine phosphate impurities, UHPLC, reversed phase, development, naproxen sodium, bilayer tablet, validation.
Graphical Abstract
[1]
Stacher, G.; Bauer, P.; Schneider, C.; Winklehner, S.; Schmierer, G. Effects of a combination of oral naproxen sodium and codeine on experimentally induced pain. Eur. J. Clin. Pharmacol., 1982, 21(6), 485-490.
[http://dx.doi.org/10.1007/BF00542043] [PMID: 7075655]
[http://dx.doi.org/10.1007/BF00542043] [PMID: 7075655]
[2]
Forbes, J.A.; Keller, C.K.; Smith, J.W.; Zeleznock, J.R.; Sevelius, H.; Beaver, W.T. Analgesic effect of naproxen sodium, codeine, a naproxen-codeine combination and aspirin on the postoperative pain of oral surgery. Pharmacotherapy, 1986, 6(5), 211-218.
[http://dx.doi.org/10.1002/j.1875-9114.1986.tb03479.x] [PMID: 3540871]
[http://dx.doi.org/10.1002/j.1875-9114.1986.tb03479.x] [PMID: 3540871]
[3]
Segre, E.J. Naproxen sodium (Anaprox): pharmacology, pharmacokinetics and drug interactions. J. Reprod. Med., 1980, 25(4)(Suppl.), 222-225.
[PMID: 7001021]
[PMID: 7001021]
[4]
Hersh, E.V.; Moore, P.A. Drug interactions in dentistry: the importance of knowing your CYPs. J. Am. Dent. Assoc., 2004, 135(3), 298-311.
[http://dx.doi.org/10.14219/jada.archive.2004.0178] [PMID: 15058617]
[http://dx.doi.org/10.14219/jada.archive.2004.0178] [PMID: 15058617]
[5]
Süzen, S.; Akay, C.; Cevheroğlu, Ş. Simultaneous determination of guaiphenesin and codeine phosphate in tablets by high-performance liquid chromatography. II Farmaco, 1999, 54(10), 705-709.
[http://dx.doi.org/10.1016/S0014-827X(99)00086-5]
[http://dx.doi.org/10.1016/S0014-827X(99)00086-5]
[6]
Vojta, J.; Hanzlík, P.; Jedlička, A.; Coufal, P. Separation and determination of impurities in paracetamol, codeine and pitophenone in the presence of fenpiverinium in combined suppository dosage form. J. Pharm. Biomed. Anal., 2015, 102(102), 85-92.
[http://dx.doi.org/10.1016/j.jpba.2014.09.002] [PMID: 25255449]
[http://dx.doi.org/10.1016/j.jpba.2014.09.002] [PMID: 25255449]
[7]
Bali, C.; Ergenoglu, P.; Ozmete, O.; Akin, S.; Ozyilkan, N.B.; Cok, O.Y.; Aribogan, A. Comparison of the postoperative analgesic effects of naproxen sodium and naproxen sodium-codeine phosphate for arthroscopic meniscus surgery. Braz. J. Anesthesiol., 2016, 66(2), 151-156.
[http://dx.doi.org/10.1016/j.bjane.2014.08.006] [PMID: 26952223]
[http://dx.doi.org/10.1016/j.bjane.2014.08.006] [PMID: 26952223]
[8]
Persson-Stubberud, K.; Aström, O. Separation of ibuprofen, codeine phosphate, their degradation products and impurities by capillary electrophoresis. I. Method development and optimization with fractional factorial design. J. Chromatogr. A, 1998, 798(1-2), 307-314.
[http://dx.doi.org/10.1016/S0021-9673(97)00955-2] [PMID: 9542142]
[http://dx.doi.org/10.1016/S0021-9673(97)00955-2] [PMID: 9542142]
[9]
Stubberud, K.; Callmer, K.; Westerlund, D. Partial filling-micellar electrokinetic chromatography optimization studies of ibuprofen, codeine and degradation products, and coupling to mass spectrometry: part II. Electrophoresis, 2003, 24(6), 1008-1015.
[http://dx.doi.org/10.1002/elps.200390116] [PMID: 12658689]
[http://dx.doi.org/10.1002/elps.200390116] [PMID: 12658689]
[10]
Diaconu, I.; Aboul-Enein, H.Y.; Bunaciu, A.A.; Tãnase, I.G. Estimation of uncertainty for measuring codeine phosphate tablets formulation using UV-Vis spectrophotometry. Anal. Lett., 2010, 43(7-8), 1207-1216.
[http://dx.doi.org/10.1080/00032710903518633]
[http://dx.doi.org/10.1080/00032710903518633]
[11]
European Pharmacopoeia, 9, 6th ed; European Directorate for the Quality of Medicines & HealthCare: Strasbourg, 2019.
[12]
Kommana, R.; Basappa, P. Validated stability indicating RP-HPLC method for simultaneous estimation of codeine phosphate and chlorpheniramine maleate from their combined liquid dosage form. Chromatogr. Res. Int., 2013, 2013, 1-7.
[http://dx.doi.org/10.1155/2013/404727]
[http://dx.doi.org/10.1155/2013/404727]
[13]
Golubitskii, G.B.; Budko, E.V.; Ivanov, V.M. Quantitative analysis of pentalgin ICN tablets by gradient and isocratic high-performance liquid chromatography. J. Anal. Chem., 2005, 60(10), 961-966.
[http://dx.doi.org/10.1007/s10809-005-0217-4]
[http://dx.doi.org/10.1007/s10809-005-0217-4]
[14]
Altun, M.L.; Ceyhan, T.; Kartal, M.; Atay, T.; Ozdemir, N.; Cevheroglu, S. LC method for the analysis of acetylsalicylic acid, caffeine and codeine phosphate in pharmaceutical preparations. J. Pharm. Biomed. Anal., 2001, (25(2001), 93-101.
[15]
Deconinck, E.; Sacré, P.Y.; Baudewyns, S.; Courselle, P.; De Beer, J. A fast ultra high pressure liquid chromatographic method for qualification and quantification of pharmaceutical combination preparations containing paracetamol, acetyl salicylic acid and/or antihistaminics. J. Pharm. Biomed. Anal., 2011, 56(2), 200-209.
[http://dx.doi.org/10.1016/j.jpba.2011.05.013] [PMID: 21665401]
[http://dx.doi.org/10.1016/j.jpba.2011.05.013] [PMID: 21665401]
[16]
Das, P.; Maity, A.; Mansuri, A. Validated RP-HPLC method for the simultaneous quantification of Paracetamol, Codeine phosphate and Caffeine in Effervescent tablet formulation. J. Pharm. Adv. Res., 2018, 1(10), 431-440.
[17]
Maslarska, V.; Tencheva, J. Simultaneous determination and validation of paracetamol and codeine phosphate in pharmaceutical preparation by RP-HPLC. Int. J. Pharm., 2013, 5(2), 417-419.
[PMID: 24012866]
[PMID: 24012866]
[18]
British Pharmacopoeia Medicines and healthcare products regulatory agency. MHRA: London, England, 2019, Vol. 1, pp., 648-649.
[19]
British Pharmacopoeia. Medicines and healthcare products regulatory agency. MHRA: London, England, 2019, Vol. 3, pp., 430-431.
[20]
USP 42-NF 37, United States PharmacopoeiaCodeine Phosphate,
The united states pharmacopeial convention; The united states by
united book press: Baltimore, United States, 2019, Vol.1, pp. 1117-
1118..
[21]
USP 42-NF 37, United States PharmacopoeiaCodeine Phosphate
Tablets, The united states pharmacopeial convention; The united
states by united book press: Baltimore, United States, 2019, Vol.1,
pp. 1118-1119..
[22]
Cheddah, S.; Hang, T. Separation and characterization of degradation/interaction products of codeine phosphate in ibuprofen arginate/codeine phosphate combination formulation by HPLC coupled with MS analysis. J. Chin. Pharm., 2014, 23(10), 694-710.
[http://dx.doi.org/10.5246/jcps.2014.10.089]
[http://dx.doi.org/10.5246/jcps.2014.10.089]
[23]
Kromidas, S. HPLC made to measure a practical handbook for; Wiley-VCH: Weinheim, Germany, 2006.
[http://dx.doi.org/10.1002/9783527611973]
[http://dx.doi.org/10.1002/9783527611973]
[25]
Sisco, W.R.; Rittenhouse, C.T.; Maggio, W.M. The rapid quantative analysis of codeine phosphate drug substance by reversed-phase high performance liquid chromatography. Chromatographia, 1985, 20(5), 289-292.
[http://dx.doi.org/10.1007/BF02310385]
[http://dx.doi.org/10.1007/BF02310385]
[26]
Malleswararao, C.S.N.; Suryanarayana, M.V.; Mukkanti, K. Simultaneous determination of ditagliptin phosphate monohydrate and metformin hydrochloride in tablets by a validated UPLC Method. Sci. Pharm., 2012, 80(1), 139-152.
[http://dx.doi.org/10.3797/scipharm.1110-13] [PMID: 22396910]
[http://dx.doi.org/10.3797/scipharm.1110-13] [PMID: 22396910]
[27]
Rathod, R.H.; Chaudhari, S.R.; Patil, A.S. Ultra-high- performance liquid chromatography-MS/MS (UHPLC-MS/MS) in practice: analysis of drugs and pharmaceutical formulations. Future J. Pharm. Sci., 2019, 5(6), 1-26.
[http://dx.doi.org/10.1186/s43094-019-0007-8]
[http://dx.doi.org/10.1186/s43094-019-0007-8]
[28]
Law, B.; Temesi, D. Factors to consider in the development of generic bioanalytical high-performance liquid chromatographic-mass spectrometric methods to support drug discovery. J. Chromatogr. B Biomed. Sci. Appl., 2000, 748(1), 21-30.
[http://dx.doi.org/10.1016/S0378-4347(00)00319-4] [PMID: 11092583]
[http://dx.doi.org/10.1016/S0378-4347(00)00319-4] [PMID: 11092583]
[29]
Kostiainen, R.; Kauppila, T.J. Effect of eluent on the ionization process in liquid chromatography-mass spectrometry. J. Chromatogr. A, 2009, 1216(4), 685-699.
[http://dx.doi.org/10.1016/j.chroma.2008.08.095] [PMID: 18799161]
[http://dx.doi.org/10.1016/j.chroma.2008.08.095] [PMID: 18799161]
[30]
Natishan, T.K. Developments in fast liquid chromatographic analysis of pharmaceuticals. J. Liq. Chromatogr. Relat. Technol., 2011, 34(13), 1133-1156.
[http://dx.doi.org/10.1080/10826076.2011.588058]
[http://dx.doi.org/10.1080/10826076.2011.588058]
[31]
Kim, Y.; Rousseau, R.W. Characterization and solid-state transformations of the pseudo polymorphic forms of sodium naproxen. Cryst. Growth Des., 2004, 4(6), 1211-1216.
[http://dx.doi.org/10.1021/cg049917q]
[http://dx.doi.org/10.1021/cg049917q]
[32]
Ravinskar, P.; Navya, C.N.; Pravallika, D.; Sri, D.N. A review on step-by-step analytical method validation. IOSR J. Pharm., 2015, 5(10), 7-19.
[33]
Ravinskar, P.; Navya, C. N.; Pravallika, D.; Sri, D. N. ICH Q1B Stability Testing: Photostability testing of new drug substance and products., 2015.
[34]
Crowther, J.B. Validation of pharmaceutical test methods.Handbook of modern pharmaceutical analysis; Ahuja, S; Scypinski, S., Ed.; Academic Press: San Diego, 2001, Vol. 3, pp. 415-443.
[http://dx.doi.org/10.1016/S0149-6395(01)80014-3]
[http://dx.doi.org/10.1016/S0149-6395(01)80014-3]
[35]
LoBrutto, R.; Patel, T. Method validation. HPLC for pharmaceutical scientists; Kazakevich, Y.; LoBrutto, R., Eds.; Wiley: Hoboken, New York, 2007, pp. 455-502..
[36]
Aksu Dönmez, Ö.; Dinç-Zor, Ş.; Aşçı, B.; Şen, E. Simultaneous HPLC-DAD determination of pseudoephedrine HCl, sodium benzoate, sunset yellow, and methyl paraben in syrup preparation by use of partial least squares and principal component regression. J. Liq. Chromatogr. Relat. Technol., 2019, 42(19-20), 648-653.
[http://dx.doi.org/10.1080/10826076.2019.1647543]
[http://dx.doi.org/10.1080/10826076.2019.1647543]
[37]
de Sauza, S.V.C.; Junqueira, R.G. A procedure to assess linearity by ordinary least squares method. Anal. Chim. Acta, 2005, 552(1-2), 25-35.
[http://dx.doi.org/10.1016/j.aca.2005.07.043]
[http://dx.doi.org/10.1016/j.aca.2005.07.043]
Article Metrics
25
1